Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -4.33%21 Days Payable is 42.48 as of Sep. 2025, which is 12% above its 10-year median of 37.87. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 115 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 86.96% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Days Payable vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cellyan Biotechnology Co's Days Payable for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a Days Payable of 42.48 as of Sep. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cellyan Biotechnology Co and its competitors. This is 12% above median its historical median of 37.87. Over the past decade, Cellyan Biotechnology Co's Days Payable has ranged from 31.11 to 52.09. According to the industry distribution chart, Cellyan Biotechnology Co ranks #100 out of 115 companies in the Medical Distribution industry, placing it in the top 87%.
Is Cellyan Biotechnology Co's Days Payable too high?
Cellyan Biotechnology Co's current Days Payable of 42.48 is 12% above median its 10-year median of 37.87. Over the past 10 years, this metric has ranged from a low of 31.11 to a high of 52.09. The Medical Distribution industry median Days Payable is 79.11. Cellyan Biotechnology Co's value of 42.48 is 46.3% below this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #100 out of 115 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Days Payable compare to COSM and SNYR?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #100 out of 115 companies for Days Payable. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median Days Payable is 79.11. Cellyan Biotechnology Co's value of 42.48 is 46.3% below this benchmark. Historically, Cellyan Biotechnology Co's own Days Payable has ranged from 31.11 to 52.09 over the past decade. While the company's 10-year median is 37.87 vs. the industry median of 79.11, Cellyan Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Distribution company?
The median Days Payable among Medical Distribution companies is 79.11, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Days Payable of 42.48 is 46.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Days Payable is 79.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Days Payable is 42.48, which is 12% above median its own 10-year median of 37.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Days Payable of 42.48. The current Days Payable is 42.48, which is 12% above median its 10-year median of 37.87 and 46.3% below the Medical Distribution industry median of 79.11. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Days Payable is 42.48 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
